Clinical Trial: Pharmacokinetic Study of QL2107 Versus Keytruda(R) for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07162883) titled 'Pharmacokinetic Study of QL2107 Versus Keytruda(R) for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)' on Aug. 31.

Brief Summary: The primary purpose of this study is to demonstrate Pharmacokinetic similarity in exposure after the initial dose and at steady state of QL2107 compared with Keytruda.

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Carcinoma, Non-Small-Cell Lung

Intervention: DRUG: QL2107

IV infusion.

DRUG: Keytruda(R)

IV infusion.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Qilu Pharmaceutical Co., Ltd.

Disclaimer: Curated by HT Syndication....